These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 1132216

  • 1. [Progress in the therapy of parkinsonism with L-dopa: inhibition of dopa decarboxylase].
    Nurzia A.
    Clin Ter; 1975 Feb 15; 72(3):289-95. PubMed ID: 1132216
    [No Abstract] [Full Text] [Related]

  • 2. L-dopa therapy in parkinsonism: mechanism of action.
    Sandler M.
    Psychiatr Neurol Neurochir; 1971 Feb 15; 74(4):331-3. PubMed ID: 5146239
    [No Abstract] [Full Text] [Related]

  • 3. [On the formation of H-3-dopa from H-3-tyrosine and determination of the dopa synthesis rate in the fowl and cat adrenal gland under in vivo conditions].
    Hempel K, Männl HF.
    Naunyn Schmiedebergs Arch Exp Pathol Pharmakol; 1967 Feb 15; 257(4):391-408. PubMed ID: 4232726
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Biochemical bases of Parkinson disease].
    Colucci d'Amato C, Puccini A, Cristillo A, Vizioli R.
    Recenti Prog Med; 1984 Oct 15; 75(10):889-901. PubMed ID: 6151219
    [No Abstract] [Full Text] [Related]

  • 7. [On the problem of the metabolism of dopamine in the brain of patients with parkinsonism].
    Travenets IA.
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1966 Oct 15; 66(10):1505-7. PubMed ID: 6000312
    [No Abstract] [Full Text] [Related]

  • 8. Drug therapy of parkinsonism.
    Bianchine JR.
    N Engl J Med; 1976 Oct 07; 295(15):814-8. PubMed ID: 958277
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Risks in the treatment of parkinsonism with l-dopa and a dopa decarboxylase inhibitor].
    Jörg J.
    Med Welt; 1979 Nov 16; 30(46):1740-2. PubMed ID: 537499
    [No Abstract] [Full Text] [Related]

  • 13. Parkinson's disease: from brain homogenate to treatment.
    Hornykiewicz O.
    Fed Proc; 1973 Feb 16; 32(2):183-90. PubMed ID: 4143953
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [L-dopa treatment in parkinsonism. Biochemical basis (author's transl)].
    Bieniowa A, Kolasa M, Reichowa J.
    Przegl Lek; 1976 Feb 16; 33(4):463-7. PubMed ID: 1273343
    [No Abstract] [Full Text] [Related]

  • 16. L-dopa-resistant Parkinsonism due to dopa decarboxylase deficiency?
    Jankovic J.
    Ann Neurol; 1981 Jul 16; 10(1):64-5. PubMed ID: 7271235
    [No Abstract] [Full Text] [Related]

  • 17. "Catecholamines" in the brain.
    Weiner WJ, Klawans HL.
    N Engl J Med; 1970 Feb 26; 282(9):513-4. PubMed ID: 5411876
    [No Abstract] [Full Text] [Related]

  • 18. [Decarboxylase inhibitors combined with L-dopa in the treatment of Parkinson's disease].
    Rondot P.
    Rev Prat; 1974 Mar 11; 24(15):1211-2, 1215-6, 1219. PubMed ID: 4416964
    [No Abstract] [Full Text] [Related]

  • 19. [Treatment of Parkinson's disease with L-dopa and with a combination of L-dopa and dopa-decarboxylase inhibitor].
    Agnoli A, Casacchia M, Reitano M, Ruggieri S, Barba C, Zamponi A.
    Minerva Med; 1972 Dec 12; 63(89):4853-61. PubMed ID: 4566743
    [No Abstract] [Full Text] [Related]

  • 20. [Psychological changes in parkinsonian patients during L-DOPA, amantidine, and L-DOPA + IDC treatment (author's transl)].
    Puca FM, Megna GF, Masi G, Specchio LM.
    Riv Patol Nerv Ment; 1974 Oct 12; 95(5):676-84. PubMed ID: 4470268
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.